U.S. Markets closed

Despite Recent Volatility, Biotech Stocks Look Poised to Pop

Casey Murphy

Biotechnology investors are no strangers to volatility, and Tuesday's price action was no exception. Followers of gene therapy companies watched one of the most popular names in the industry lose approximately one-third of its value due to patient safety concerns. As alluded to above, shares of Spark Therapeutics dropped sharply in Tuesday's trading session due to heightened patient safety concerns surrounding a hemophilia gene therapy trial.